Pierre Geborek

affiliated with the university
More filtering options
  1. 2011
  2. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial

    Saedis Saevarsdottir, Helena Wallin, Maria Seddighzadeh, Sofi A. Ernestam, Pierre Geborek, Ingemar Petersson, Johan Bratt & Ronald F. van Vollenhoven, 2011, In : Annals of the Rheumatic Diseases. 70, 3, p. 469-475

    Research output: Contribution to journalArticle

  3. Prevalence of spondyloarthritis and its subtypes in southern Sweden

    Emma Haglund, Ann Bremander, Ingemar Petersson, Britta Strömbeck, Stefan Bergman, Lennart Jacobsson, Aleksandra Turkiewicz, Pierre Geborek & Martin Englund, 2011, In : Annals of the Rheumatic Diseases. 70, p. 943-948

    Research output: Contribution to journalArticle

  4. Ten years with biologics: to whom do data on effectiveness and safety apply?

    Julia F Simard, Elizabeth V Arkema, Anders Sundström, Pierre Geborek, Tore Saxne, Eva Baecklund, Lars Coster, Christina Dackhammar, Lennart Jacobsson, Nils Feltelius, Staffan Lindblad, Solbritt Rantapää-Dahlqvist, Lars Klareskog, Ronald F van Vollenhoven, Martin Neovius & Johan Askling, 2011, In : Rheumatology (Oxford, England). Dec, p. 204-213

    Research output: Contribution to journalArticle

  5. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials.

    Lars Erik Kristensen, Ak Jakobsen, Em Bartels, Pierre Geborek, H Bliddal, Tore Saxne, B Danneskiold-Samsøe & R Christensen, 2011, In : Scandinavian Journal of Rheumatology. 40, p. 1-7

    Research output: Contribution to journalArticle

  6. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases

    S. van Assen, O. Elkayam, N. Agmon-Levin, R. Cervera, M. F. Doran, M. Dougados, P. Emery, Pierre Geborek, J. P. A. Ioannidis, D. R. W. Jayne, C. G. M. Kallenberg, U. Mueller-Ladner, Y. Shoenfeld, L. Stojanovich, G. Valesini, N. M. Wulffraat & M. Bijl, 2011, In : Autoimmunity Reviews. 10, 6, p. 341-352

    Research output: Contribution to journalReview article

  7. 2010
  8. Elevated neutrophil membrane expression of proteinase 3 is dependent upon CD177 expression.

    Mohamed AbdGawad, Lena Gunnarsson, Anders Bengtsson, Pierre Geborek, L Nilsson, Mårten Segelmark & Thomas Hellmark, 2010, In : Clinical and Experimental Immunology. 161, p. 89-97

    Research output: Contribution to journalArticle

  9. 2009
  10. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

    R. F. van Vollenhoven, S. Ernestam, Pierre Geborek, Ingemar Petersson, L. Coster, E. Waltbrand, A. Zickert, J. Theander, A. Thorner, H. Hellstrom, A. Teleman, C. Dackhammar, F. Akre, K Forslind, L. Ljung, R. Oding, A. Chatzidionysiou, M. Wornert & J. Bratt, 2009, In : The Lancet. 374, 9688, p. 459-466

    Research output: Contribution to journalArticle

  11. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas:relative risks and time-trends in the Swedish Biologics Register

    J Askling, E Baecklund, F Granath, Pierre Geborek, M. Fored, C Backlin, L Bertilsson, L Coster, L Jacobsson, S Rantapaa-Dahlqvist, Tore Saxne, R van Vollenhoven, L Klareskog & N Feltelius, 2009, In : Annals of the Rheumatic Diseases. 68, 5, p. 648-653 6 p.

    Research output: Contribution to journalArticle

  12. Geriatric rheumatoid arthritis patients on delayed anti-TF-alpha agents have higher disease activity and experience more often serious adverse events compared to younger adults

    Irini Flouri, Alexandros Drosos, Kyriaki Boki, Fotini Skopouli, Dimitrios Karras, Ioannis Papadopoulos, Pierre Geborek, Symeon Panagiotakis, Dimitrois T. Boumpas & Prodromos Sidiropoulos, 2009, In : Clinical and Experimental Rheumatology. 27, 5, p. 705-706

    Research output: Contribution to journalPublished meeting abstract

  13. Long-term follow-up of RA patients of the Hellenic Biologics Registry: comparison of first versus second anti-TNF-alpha therapy

    Prodromos Sidiropoulos, Irini Flouri, Alexandros Drosos, Kyriaki Boki, Ioannis Papadopoulos, Fotini Skopouli, Florentia Kanakoudi, Dimitrios Karras, Iraklis Kritikos, Pierre Geborek & Dimitrios Boumpas, 2009, In : Clinical and Experimental Rheumatology. 27, 5, p. 708-708

    Research output: Contribution to journalPublished meeting abstract

  14. Studies of mechanisms underlying the prolonged neutrophil survival in ANCA-associated systemic vasculitis

    Mohamed AbdGawad, Lena Gunnarsson, Anders Bengtsson, Pierre Geborek, Mårten Segelmark & Thomas Hellmark, 2009, In : APMIS. 117, p. 125-125

    Research output: Contribution to journalPublished meeting abstract

  15. 2008
  16. The Swedish biologics register (ARTIS): observations of adverse events when using biologics in clinical practice

    Eva Baecklund, Johan Askling, Lennart Bertilsson, Lars Coster, Nils Feltelius, Michael Fored, Pierre Geborek, Lennart T Jacobsson, Lars Klareskog, Staffan Lindblad, Jorgen Lysholm, Solbrutt Rantapaa-Dahlqvist, Tore Saxne & Ronald van Vollenhoven, 2008, In : Scandinavian Journal of Rheumatology. 37, Suppl. 123, p. 12-12

    Research output: Contribution to journalPublished meeting abstract

  17. Why do women with early RA respond less well to MTX than men? Gender as a determinant of response in the initial phase of the Swefot trial

    Ronald van Vollenhoven, Sofia Emestam, Lars Coester, Christina Dackhammar, Kristina Forslind, Pierre Geborek, Helena Hellstroem, Lotta Ljung, Rolf Oding, Ingemar Petersson, Annika Teleman, Jan Theander, Ake Thorner, Bo Tornqvist, Eva Waltbrand, Agneta Zickert, Margareta Wornet & Johan Bratt, 2008, In : Scandinavian Journal of Rheumatology. 37, Suppl. 123, p. 52-52

    Research output: Contribution to journalPublished meeting abstract

  18. 2007
  19. Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation

    Klaus Bendtzen, Pierre Geborek, Morten Svenson, Lotta Larsson, Meliha C Kapetanovic & Tore Saxne, 2007, In : Ugeskrift for Laeger. 169, 5, p. 420-423

    Research output: Contribution to journalArticle

  20. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists

    Johan Askling, C. Michael Fored, Lena Brandt, Eva Baecklund, Lennart Bertilsson, Nils Feltelius, Lars Coster, Pierre Geborek, Lennart Jacobsson, Staffan Lindblad, Jorgen Lysholm, Solbritt Rantapaa-Dahlqvist, Tore Saxne, Ronald F. van Vollenhoven & Lars Klareskog, 2007, In : Annals of the Rheumatic Diseases. 66, 10, p. 1339-1344

    Research output: Contribution to journalArticle

  21. Treatment with TNF-blockers and mortality risk in patients with rheumatoid arthritis.

    Lennart Jacobsson, Carl Turesson, Jan-Åke Nilsson, Ingemar Petersson, Elisabet Lindqvist, Tore Saxne & Pierre Geborek, 2007, In : Annals of the Rheumatic Diseases. 66, 5, p. 670-675

    Research output: Contribution to journalArticle

  22. 2006
  23. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

    Klaus Bendtzen, Pierre Geborek, Morten Svenson, Lotta Larsson, Meliha C. Kapetanovic & Tore Saxne, 2006, In : Arthritis and Rheumatism. 54, 12, p. 3782-3789

    Research output: Contribution to journalArticle

  24. Predictors of infusion reactions during infliximab treatment in patients with arthritis.

    Meliha C Kapetanovic, Lotta Larsson, Lennart Truedsson, Gunnar Sturfelt, Tore Saxne & Pierre Geborek, 2006, In : Arthritis Research and Therapy. 8, p. 1-7 R131.

    Research output: Contribution to journalArticle

  25. Swedish registers to examine drug safety and clinical issues in RA

    J Askling, CM Fored, Pierre Geborek, LTH Jacobsson, R van Vollenhoven, N Feltelius, S Lindblad & L Klareskog, 2006, In : Annals of the Rheumatic Diseases. 65, 6, p. 707-712

    Research output: Contribution to journalReview article

  26. 2005
  27. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

    J Askling, CM Fored, E Baecklund, L Brandt, C Backlin, A Ekbom, C Sundstrom, L Bertilsson, L Coster, Pierre Geborek, LT Jacobsson, S Lindblad, J Lysholm, S Rantapaa-Dahlqvist, Tore Saxne, L Klareskog & N Feltelius, 2005, In : Annals of the Rheumatic Diseases. 64, 10, p. 1414-1420

    Research output: Contribution to journalArticle

  28. No increase of severe infections in RA patients treated with TNF-blockers

    L T H Jacobsson, C Turesson, Anders Gülfe, M C Kapetanovic, Ingemar Petersson, Tore Saxne & Pierre Geborek, 2005, In : Annals of the Rheumatic Diseases. 64, Suppl. 3, p. 461-462

    Research output: Contribution to journalPublished meeting abstract

  29. Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales

    Pierre Geborek, E Nitelius, S Noltorp, H Petri, L Jacobsson, L Larsson, Tore Saxne & I Leden, 2005, In : Annals of the Rheumatic Diseases. 64, 12, p. 1805-1807

    Research output: Contribution to journalLetter